Dr John LaMattina Joins Ziarco as Strategic Advisor

Ziarco has appointed pharma leader and former President of Pfizer Global R&D, Dr John L. LaMattina as Strategic Advisor.

Ziarco, a recently-launched biopharmaceutical company focusing on steroid-unresponsive inflammation and allergic diseases, has appointed pharma leader and former President of Pfizer Global R&D, Dr John L. LaMattina as Strategic Advisor. His role at Ziarco will be to provide input on the company's corporate, R&D strategy and growth plans.
 Commenting on his appointment, Dr LaMattina said: "Ziarco has amassed an excellent portfolio of early drug candidates with great potential. I am very much looking forward to working with the Ziarco team to convert these assets into valued new medicines."
 Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that John is joining the team as a Strategic Advisor. Under his inspirational leadership during his long career at Pfizer, not only were several excellent medicines discovered and developed, but many of what are now industry-recognised R&D best-practises were established, as were many future leaders also. His expertise will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."
 John L. LaMattina, PhD
 Dr. LaMattina is a Senior Partner at PureTech and was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc.
 During Dr. LaMattina’s leadership tenure Pfizer advanced a number of important new medicines including Chantix, Selzentry, Lyrica, Inlyta, Xalkori and Xaljenz. He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued & Distrusted – Can the pharma industry restore its broken image.” Dr. LaMattina serves on the Board of Directors of Ligand Pharmaceuticals, Vedanta and Gelesis, and is a member of the Scientific Advisory Board of Trevena Pharmaceuticals.